Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib

Medicine and Dentistry

• Fibroblast Growth Factor Receptor 1 100%
• Myeloproliferative Disorder 100%
• Therapeutic Procedure 60%
• Tyrosine-Kinase Inhibitor 60%
• Patient 40%
• Therapeutics 20%
• Transplantation 20%
• In Vitro 20%
• Chemotherapy 20%
• Donor 20%
• Chromosome Analysis 20%

Immunology and Microbiology

• Fibroblast Growth Factor Receptor 1 100%
• Transplant Procedure 20%
• Allogeneic Stem Cell Transplantation 20%
• Polymerase Chain Reaction 20%
• Chromosome 20%
• Bone Marrow 20%
• Chromosome 8 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Protein Tyrosine Kinase Inhibitor 100%
• Neoplasm 33%
• Chemotherapy 33%
• Acute Myeloid Leukemia 33%